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Abstract
Background: Tumor cell expression of Toll-like receptors (TLRs) can promote inflammation and cell survival in the 
tumor microenvironment. Toll-like receptor 4 (TLR4) signaling in tumor cells can mediate tumor cell immune escape 
and tumor progression, and it is regarded as one of the mechanisms for chronic inflammation in tumorigenesis and 
progression. The expression of TLR4 in human breast cancer cell line MDA-MB-231 and its biological function in the 
development and progression of breast cancer have not been investigated. We sought to characterize the expression 
of TLR1-TLR10 in the established human breast cancer cell line MDA-MB-231, and to investigate the biological roles of 
TLR4 in breast cancer cells growth, survival, and its potential as a target for breast cancer therapy.
Methods: TLRs mRNA and protein expressions were detected in human breast cancer cell line MDA-MB-231 by RT-
PCR, real-time PCR and flow cytometry (FCM). RNA interference was used to knockdown the expression of TLR4 in 
MDA-MB-231. MDA-MB-231 transfected with the vector pGenesil-1 and the vector containing a scrambled siRNA were 
as controls. Recombinant plasmids named TLR4AsiRNA, TLR4BsiRNA and TLR4CsiRNA specific to TLR4 were transfected 
into human breast cancer cell line MDA-MB-231 with Lipfectamine™2000 reagent. TLR4 mRNA and protein expressions 
were investigated by RT-PCR, real-time PCR, FCM and immunofluorescence after silence. MTT analysis was performed 
to detect cell proliferation and FCM was used to detect the secretion of inflammatory cytokines in supernatant of 
transfected cells.
Results: The human breast cancer cell line MDA-MB-231 was found to express TLR1-TLR10 at both the mRNA and 
protein levels. TLR4 was found to be the highest expressed TLR in MDA-MB-231. TLR4AsiRNA, TLR4BsiRNA and 
TLR4CsiRNA were found to significantly inhibit TLR4 expression in MDA-MB-231 at both mRNA and protein levels as 
compared to vector control(vector transfected cells). TLR4AsiRNA mediated the strongest effect. Knockdown of TLR4 
gene in MDA-MB-231 resulted in a dramatic reduction of breast cancer cell viability. The cytokines which were secreted 
by the TLR4 silenced cells, such as IL-6 and IL-8, also decreased significantly as compared with vector control. No 
significant difference was observed in siRNA control (Recombinant plasmid named ScrambledsiRNA transfected cells) 
compared to vector control.
Conclusions: These studies identified the expression levels of multiple TLRs in human breast cancer cell line MDA-MB-
231 and demonstrated that knockdown of TLR4 could actively inhibit proliferation and survival of breast cancer cells. 
Taken together, our results suggest RNAi-directed targeting of TLR4 may be a beneficial strategy for breast cancer 
therapy.
Introduction
Human toll-like receptors (TLRs), firstly identified in
mammalian immune cells, are a family of type I trans-
membrane proteins comprised of an extracellular domain
with a leucine-rich repeat region and an intracellular
domain homologous to that of the human interleukin
(IL)-1 receptor [1]. TLRs have a powerful capacity to
innate immune responses [2] through recognition of
pathogen-associated molecular patterns (PAMP)
* Correspondence: sdfeyjyk@yahoo.com.cn
1 Department of Clinical Laboratory, The Second affiliated Hospital of Soochow 
University, Suzhou, Jiangsu, China
Full list of author information is available at the end of the articleYang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
http://www.jeccr.com/content/29/1/92
Page 2 of 8
expressed by bacteria and viruses, and host-derived
PAMPs [3]. Until now, 11 types of mammalian homo-
logues have been identified and characterized [4].
Recently, new evidence has revealed that TLRs exist in
many mouse [5] and human tumors [6-9], such as lung
cancer, prostate cancer, neuroblastoma and breast cancer
[10]. Although the TLR profile varies in different tumor
cells, current evidence indicates that the expression of
TLRs and signaling cascade are functionally associated
with tumor growth, progression, and invasion. For exam-
ple, TLR2 signaling has been shown to promote lung can-
cer cell growth and resistant of apoptosis [11]; TLR3 can
directly trigger apoptosis in human cancer cells, such as
breast cancer cells [12], TLR2 and TLR9 can promote
invasiveness and metastasis through metalloproteases
and integrins [13,14].
Breast cancer is one of the common tumors occurring
in women which is incurable and ultimately claims the
life of the patient with complications. Thus, there is a
need for new and effective breast cancer therapies. As
TLRs are widely expressed on tumor cells and play
important roles in the initiation and progression of can-
cer, they may thus serve an important target and have an
effective perspective on breast cancer treatment.
Therefore, in this study, we aimed to determine which
TLRs were expressed in human breast cancer cell line
MDA-MB-231 and whether TLR4 played a functional
role in the growth and progression of MDA-MB-231. A
plasmid vector pGenesil-1 was developed to express a
panel of siRNAs directed against TLR4. We planned to
exploit the fact that small-interfering RNA (siRNA) can
specifically inhibit gene expression with high efficiency
[15] and use it as an experimental tool to dissect the cel-
lular pathways that lead to uncontrolled cell proliferation
of breast cancer.
Materials and methods
Cell line and cell culture
Human breast cancer cell line MDA-MB-231 was pur-
chased from the cell bank of Academia Sinica (Taipei,
Taiwan). MDA-MB-231 was grown without antibiotics in
5% CO2 at 37°C in RPMI-1640 (Gibco, CA, USA) contain-
ing 10% FBS.
Qualitative RT-PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, CA, USA) and the first-strand cDNA was synthe-
sized according to the manufacturer's instructions using
4 μg total RNA with an oligo-dT primer and the myelo-
blastosis virus (MLV) reverse transcriptase (Promega,
WI, USA). The PCR primers for TLRs (from TLR1 to
TLR10) and GAPDH were intron-spanning, and are
listed in Table 1. PCR products were analyzed on 1-2%
(wt/vol) agarose gels containing 0. 5 μg/ml ethidium bro-
mide and were visualized under UV light.
Real-time RT-PCR
Real-time RT-PCR was performed to detect TLRs gene
expression. The 50 μl reaction mixture contained 45 μl
DEPC-H2O, 1.0 μl cDNA (1:100 dilution), 2.0 μl (10 μM)
of each primer and freeze-dried powder of the Accu-
Power Greenstar® qPCR premix. The thermal cycle pro-
file for PCR was as follows: 94°C for 5 min, 40 cycles of
PCR (94°C for 30 sec; 55°C for 30 sec; 72°C for 30 sec).
The fluorescence was digitally collected after each cycle
of 72°C for 30 sec. After PCR, the samples were subjected
to a temperature ramp with continuous fluorescence
monitoring for melting curve analysis. BIONEER Exicy-
cler™ analysis software (Bioneer Corp., Daejeon, Korea)
was used to obtain the Ct values. 2-ΔΔ CT method [16] was
used to analyze the relative expression of each TLR in
MDA-MB-231.
TLRs protein expression analysis
To detect the cell protein expression of TLRs, 106 cul-
tured MDA-MB-231 were prefixed and permeabilized.
Then, the cells were stained with 3 μl purified anti-
human TLR4 antibody (Santa Cruz Biotechnology, CA,
USA) at 4°C for 30 min away from light. After washing
Table 1: PCR primers of human TLRs
Genes Primer sequence (5'-3') Amplification 
size (bp)
TLR1 For: TCTGGTACACGCATGGTC 517 bp
Rev: ATGGGTGGGAAACTGAAT
TLR2 For: AACTTACTGGGAAATCCTTAC 264 bp
Rev: AAAAATCTCCAGCAGTAAAAT
TLR3 For: GCATTTGTTTTCTCACTCTTT 131 bp
Rev: TTAGCCACTGAAAAGAAAAAT
TLR4 For: CGAGGAAGAGAAGACACCAGT 106 bp
Rev: CATCATCCTCACTGCTTCTGT
TLR5 For: AGCTTCAACTATATCAGGACA 383 bp
Rev: TGGTTGGAGGAAAAATCTAT
TLR6 For: CTTCCATTTTGTTTGCCTTAT 123 bp
Rev: AGCGGTAGGTCTTTTGGAAC
TLR7 For: AAACTCCTTGGGGCTAGATG 149 bp
Rev: AGGGTGAGGTTCGTGGTGTT
TLR8 For: CTGTGAGTTATGCGCCGAAGA 246 bp
Rev: TGGTGCTGTACATTGGGGTTG
TLR9 For: CGCCCTGCACCCGCTGTCTCT 168 bp
Rev: CGGGGTGCTGCCATGGAGAAG
TLR10 For: AGAAGAAAGGGAACTGATGAC 279 bp
Rev: CCTGCCAGTAAATACCAAGT
GAPDH For: GGATTTGGTCGTATTGGG 205 bp
Rev: GGAAGATGGTGATGGGATTYang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
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twice with 1×PBS, the cells were incubated with 2 μl PE-
conjugated goat anti-rabbit IgG mAb (Santa Cruz Bio-
technology) at 4°C for 30 min away from light, followed
by an additional two washes with 1×PBS. Finally, the
stained cells in 500 μl 1×PBS were analyzed by using a
flow cytometer (FACScalibur; Becton Dickinson (BD),
NJ, USA), and the data were processed with BD Cell-
Quest software. The negative control was performed by
omitting the anti TLR4 antibody.
Immunofluorescence analysis
Cells cultured overnight were fixed with alcohol for 30
min and blocked in 1×PBS (pH 7.4) solution with 3% BSA
overnight at 4°C in a hydrated box. Anti-TLR4 antibody
was added at a 1:100 dilution (Santa Cruz Biotechnology)
and allowed to incubate overnight at 4°C in a hydrated
box. After washing three times, fluorescent secondary
antibody (Santa Cruz Biotechnology) was added at a
1:100 dilution. The cells were again washed three times
with 1×PBS, and counter-stained with DAPI. Fluores-
cence was analyzed by fluorescence microscope
(DMI4000B; Leica, IL, USA). Adobe Photoshop 9.0 soft-
ware (CA, USA) was used for subsequent image process-
ing.
RNA interference
Cells were transiently transfected with a GFP expressing
plasmid pGsil-1 (Genesil, Wuhan, China) containing
silencing RNA (siRNA) directed against TLR4. The three
pieces of small interfering oligonucleotide specific for
human TLR4 have been listed in Table 2 . Briefly, 2×105
cells were seeded in 6-well dishes and cultured overnight
until 60% to 70% confluency was reached. Transfections
were performed using Lipofectamine™ 2000 reagent
(Invitrogen) per the manufacturer's instructions. Cells
were transfected with 4 μg plasmid DNA (TLR4AsiRNA,
TLR4BsiRNA, TLR4CsiRNA, vector pGenesil-1 and
ScrambledsiRNA) using 8 μl transfection reagent. After
48 h of transfection, fluorescence of cells was observed by
a fluorescence microscope. Then, cells were seeded for
FCM and immunofluorescence assay. Supernatant was
collected to test the inflammatory cytokines secreted by
the cells.
MTT assay
Cells were seeded into 96-well culture plates (6×103/well,
5 wells repeated), allowed to adhere overnight, and then
transfections were performed according to the manufac-
turer's instructions. After 48 h, the transfected cells were
collected (0 h) or allowed to continue in culture for 24 h,
48 h, or 72 h. At the end of each treatment, cells were
incubated with 5 mg/mL MTT (Sigma Chemical Co.,
MO, USA) for 4 h and then mixed with dimethyl sulfox-
ide after the supernatant was removed. The dye absorp-
tion (A) was quantitated using an automatic microplate
spectrophotometer (340 st; Anthos Zenyth, Salzburg,
Austria) at 490 nm.
Human inflammatory cytokine assay
IL-6 and IL-8 presence in the supernatant of transfected
cells were detected according to the instruction of human
inflammatory cytokine kit (BD™ Cytometric Bead Array
(CBA)). FACScan flow cytometer (BD) was used to ana-
lyze samples.
Statistical Analysis
GraphPad Prism software (CA, USA) was used to per-
form statistical comparisons between different values.
Data were expressed as the means ± standard deviation
(SD) with n = 3. Statistical significances were determined
by Student's t-test and ANOVA, differences were consid-
ered significant at a P value of less than 0.05.
Results
Expression of TLRs in human breast cancer cell line MDA-
MB-231
As TLRs have been identified in some tumor cells, we
sought to detect if they were expressed in the human
breast cancer cell line MDA-MB-231. Qualitative RT-
PCR analysis revealed that MDA-MB-231 expressed
mRNA of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7,
TLR8, TLR9 and TLR10 (Figure 1A). Real-time PCR anal-
ysis revealed the relative expressions of each TLR exam-
ined. The expression of TLR3 was normalized to 1.0, as it
was expressed the most weakly. TLR4 was 5-fold higher
than TLR3, while other TLRs were expressed between 1-
and 4-fold higher than TLR3 (Figure 1B). By FCM detec-
tion, we were able to examine the different protein
expression levels of the TLRs, TLR4, TLR6, TLR7 and
TLR5 were expressed moderately; the other TLRs were
expressed weakly or unexpressed. Again, TLR4 protein
level was the highest out of TLR1-TLR10 (Figure 1C).
Collectively, these results demonstrated that MDA-MB-
231 expressed all the TLRs examined (TLR1-TLR10) and
TLR4 was expressed highest. TLR4 was strategically
selected to investigate its function on the growth and pro-
gression of MDA-MB-231 in subsequent studies.
Table 2: sequences of siRNA against TLR4
Name 
of siRNA
TLR4 
sequences(5'-3')
Site 
position
TLR4A a a c t t g t a t t c a a g g t c t g g c 1023-1044
TLR4B a a g g c t t a c t t t c a c t t c c a a 1374-1395
TLR4C a a c t c c c t c c a g g t t c t t g a t 1921-1942Yang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
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Figure 1 mRNA and protein expression levels of TLRs (TLR1 through TLR10) in human breast cancer cell line MDA-MB-231. A, semi-quanti-
tative RT-PCR of TLRs in MDA-MB-231. The GAPDH mRNA was amplified as control. B, real-time RT-PCR of TLRs in MDA-MB-231. The expression of TLR3 
was normalized to 1.0 as it was expressed weakest among all TLRs. C, Flow cytometry of TLRs protein expression levels in MDA-MB-231. All results are 
representative of three separate experiments.Yang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
http://www.jeccr.com/content/29/1/92
Page 5 of 8
Efficient knockdown of TLR4 expression by three siRNAs in 
human breast cancer cell line MDA-MB-231
To study the biological role of TLR4 in the progression of
human breast cancer cell line MDA-MB-231, we con-
structed pGenesil-1 plasmid vectors expressing three dif-
ferent siRNAs directed against TLR4 [GenBank:
NM_138554.3] to selectively reduce TLR4 gene expres-
sion in MDA-MB-231. The regions have no significant
homology to other coactivators or sequences in the
human genome database. The vector, TLR4AsiRNA,
TLR4BsiRNA, TLR4CsiRNA and ScrambledsiRNA were
transfected into MDA-MB-231. After 48 h, the trans-
fected cells appeared to fluoresce green under the fluo-
rescence microscope. Transfection efficiency reached
about 70%. From RT-PCR we could see that there were
different reductions in TLR4AsiRNA, TLR4BsiRNA,
TLR4CsiRNA transfected cells (Figure 2A). Figure 2B
showed us that the decreased expression of TLR4 at
mRNA levels for TLR4AsiRNA, TLR4BsiRNA and
TLR4CsiRNA was 74.8 ± 9.2%, 55.2 ± 6.7% and 63.0 ±
8.3% as compared to vector control (P < 0.05). However,
no significant difference was observed in siRNA control
(P > 0.05). As shown in Figure 2C, analysis of the trans-
fected cells for TLR4 expression via FCM demonstrated
that specific reductions at protein level for TLR4AsiRNA,
TLR4BsiRNA and TLR4CsiRNA was 53.0% ± 2.9%, 37.9%
± 3.7% and 46.7% ± 4.6% as compared to vector control (P
< 0.05). No obvious difference was seen in siRNA control
(P > 0.05). Human beast cancer cell line MDA-MB-231
showed that siRNA-directed knockdown of the TLR4
gene was specific. TLR4AsiRNA was the most efficient
recombinant plasmid in silencing TLR4 and it was cho-
sen for use in subsequent functional assay.
TLR4 knock down inhibited proliferation and secretion of 
inflammatory cytokines in the supernatant of transfected 
human breast cancer cell line MDA-MB-231
Real-time PCR had demonstrated a specific reduction at
mRNA level for TLR4AsiRNA. We further analyzed the
effects of TLR4AsiRNA on TLR4 protein expression in
MDA-MB-231 using immunostaining with anti-TLR4
antibody. Red fluorescence of TLR4 staining under the
fluorescence microscope was drastically reduced by
TLR4AsiRNA in comparison to vector control. No obvi-
ous difference was seen in siRNA control (Figure 3A). To
access the potential effects of TLR4AsiRNA-mediated
TLR4 silencing on cell proliferation and survival, MTT
analysis was performed on the cells cultured 0 h, 24 h, 48
h, and 72 h following 48 h of transfection. Targeting of
TLR4AsiRNA against TLR4 effected the proliferative
ability of MDA-MB-231 (Figure 3B). The proliferative
rate was significantly decreased according to the time of
culture after transfection with TLR4AsiRNA compared
with vector control; no significant difference was
observed in siRNA control (P > 0.05). The biological con-
sequences caused by TLR4 silencing may be a result of
changes in TLR4-mediated signaling and subsequent
downstream functions. Because increased TLR4 activates
TLR4/MyD88 signaling and subsequent downstream
functions [17], we decided to examine the status of the
TLR4-related inflammatory cytokines in MDA-MB-231
with TLR4 gene knockdown. Analysis of FCM revealed
that IL-6 and IL-8 were markedly depressed in the super-
natant of silenced cells. The inhibition ration of cytokine
IL-6 and IL-8 was 47.8 ± 3.9% and 48.3 ± 4.1% respec-
tively when compared with vector control (P < 0.05), no
significant difference was seen in siRNA control (Figure
3C and Figure 3D). These results suggested that
decreased TLR4 levels in tumor cells might endow cells
with attenuated growth and survival capacity.
Discussion
Recently, much attention has been paid to TLRs and their
potential role in different cancers. However, investiga-
tions of TLRs and breast cancer are limited. Merrell. et al.
[10] showed that TLR9 protein is expressed in human
b r e a s t  c a n c e r  c e l l s  a n d  c l i n i c a l  b r e a s t  c a n c e r  s a m p l e s .
Stimulation of TLR9-expressing breast cancer cells with
the TLR9 agonistic CpG oligonucleotides dramatically
increased their in vitro invasion capacity in both Matrigel
assays and three-dimensional collagen cultures. Ilvesaro.
et al. [18] suggested that TLR9 expression was increased
in breast cancer and that CpG oligonucleotide-induced
cellular invasion was mediated via TLR9 and TRAF6,
independent of MyD88. Xie. et al. [19] showed that TLR2
was highly expressed in MDA-MB-231 cells as compared
with the MCF-7 breast cancer cell line, and concluded it
played a critical role in the cell invasion properties of
these cells.
From these studies, we know that TLR9 and TLR2 play
a key role in breast cancer proliferation and metastasis.
However, the conclusions from different studies are dis-
cordant. The growth, proliferation and metastasis of
breast cancer are complex and dynamic processes and are
likely to be associated with the actions (and interplay) of
several TLRs. Not only TLR9 and TLR2, but also other
TLRs are involved in the process of breast cancer devel-
opment. We need to systematically explore the TLR
expression profiles of breast cancer cells in order to inves-
tigate the relationship between TLRs and the growth,
progression and survival of breast cancer cells.
We found that TLRs including TLR1, TLR2, TLR3,
TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10 were
widely expressed in MDA-MB-231 at both the mRNA
and protein levels. Real-time PCR analysis and flow
cytometry detection showed that TLR4 was the highest
expressed. However, the results of TLRs expression ofYang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
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Figure 2 Transfection and silencing of TLR4 expression using three different siRNAs in human breast cancer cell line MDA-MB-231. A, RT-
PCR of TLR4 from pGenesil-1 vector, ScrambledsiRNA, TLR4AsiRNA, TLR4BsiRNA and TLR4CsiRNA transfected MDA-MB-231. B, the decreased expres-
sion of TLR4 at mRNA level in pGenesil-1 vector, ScrambledsiRNA, TLR4AsiRNA, TLR4BsiRNA and TLR4CsiRNA transfected MDA-MB-231 with real-time 
PCR. C, analysis of transfected cells for TLR4 expression by flow cytometry. All results are representative of three separate experiments.Yang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
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MDA-MB-231 were different from the conclusions of
Xie. et al [19].
People have reported that TLR4 is an important mem-
ber of TLRs and has been shown to be present in tumors,
such as ovarian cancer [17], prostate cancer cell [20] and
colorectal cancer cell [21,22]. The activation of TLR4
expressed on tumor cells may promote tumor growth and
resistant of apoptosis. Kelly. et a1 [17] found that activa-
tion of TLR4 signaling promotes the growth and
chemoresistance of epithelial ovarian cancer cells. Block-
age of TLR4 signaling has been shown to delay tumor
growth and prolong the survival of animals [23,24]. In
contrast, in a two-stage chemical carcinogenesis mouse
model, in which inflammation mediated the promotion
phase of lung cancer, the presence of a functional TLR4
was shown to inhibit lung carcinogenesis, suggesting a
p r o t e c t i v e  r o l e  o f  T L R 4  i n  t h i s  m o d e l  o f  c a n c e r  [ 2 5 ] .
Therefore, we firstly selected TLR4 to explore whether it
was able to either promote or suppress the growth of
human breast cancer cell line MDA-MB-231.
Because of the high expression of TLR4 in MDA-MB-
231, we choosed RNAi to knockdown the expression of
TLR4 to observe the biological character of silenced cells.
Three specific pieces of siRNAs successfully decreased
TLR4 gene expression and TLR4AsiRNA was the most
efficient recombinant plasmid. Functional analysis in our
study revealed that the abrogation of TLR4 expression
inhibited growth and proliferation strongly. TLR4 played
a positive role in the progression of breast cancer cells.
Previous studies have reported that when tumor cells
are stimulated with lipopolysaccharides (LPS), the ligand
for TLR4, the proinflammatory factors such as nitric
oxide, IL-6 and IL-12 are expected to be released from
tumor cells, attracting and activating inflammatory cells.
Figure 3 TLR4 expression and functional effect after TLR4 knockdown in human breast cancer cell line MDA-MB-231. A, immunofluorescence 
analysis of gene-specific siRNA on TLR4 protein expression in pGenesil-1 vector, ScrambledsiRNA and TLR4AsiRNA transfected cells. Nuclear staining 
was performed using DAPI (blue) (200×). B, MTT analysis of the proliferative rate of pGenesil-1 vector, ScrambledsiRNA and TLR4AsiRNA transfected 
cells. C and D, IL-6 and IL-8 presence in the supernatant secreted by pGenesil-1 vector, ScrambledsiRNA and TLR4AsiRNA transfected cells. Cell super-
natant was analyzed using flow cytometry. All results are representative of three separate experiments.Yang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:92
http://www.jeccr.com/content/29/1/92
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Moreover, these factors are known to contribute to the
resistance of tumor cells to cytotoxic T lymphocyte
(CTL) and natural killer cell (NKC) attack and facilitate
evasion from immune surveillance[5]. In our study, TLR4
knockdown in vitro lead to TLR4-related inflammatory
cytokines being markedly depressed and so it could
weaken the ability to the resistance of MDA-MB-231 to
CTL and NKC attack and facilitate evasion from immune
surveillance. This occurrence in vitro may indicate us that
TLR4 knockdown in vivo could inhibit the growth and
promote the death of breast tumors.
Conclusions
TLR4-mediated cancer growth appears to be an impor-
tant factor in tumor progression. The use of systemically
delivered TLR4-siRNA may provide a novel approach to
preventing cancer progression and survival.
TLR4AsiRNA directed targeting of TLR4 is a promising
candidate for molecular therapy of breast cancer.
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